TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:44
ADIAL PHARMACEUTICALS INC. ( ADIL ) https://www.adialpharma.com
1.05USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-40.68%
ADIL
SPY
32.66%
-98.31%
ADIL
SPY
108.59%
-98.29%
ADIL
SPY
302.52%
ADIL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
6.13
0.92
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.47
190.02
1.04
-652.62
0.00
-0.11
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-7093.07
-0.44
-6632.32
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.5824
-205.82
-213.20
1.43
Other Earnings and Cash Flow Stats:
ADIAL PHARMACEUTICALS INC. ( ADIL ) Net Income TTM ($MM) is -13.05
ADIAL PHARMACEUTICALS INC. ( ADIL ) Operating Income TTM ($MM) is -8.13
ADIAL PHARMACEUTICALS INC. ( ADIL ) Owners' Earnings Annual ($MM) is 0.00
ADIAL PHARMACEUTICALS INC. ( ADIL ) Current Price to Owners' Earnings ratio is 0.00
ADIAL PHARMACEUTICALS INC. ( ADIL ) EBITDA TTM ($MM) is -8.07
ADIAL PHARMACEUTICALS INC. ( ADIL ) EBITDA Margin is -6632.32%
Capital Allocation:
ADIAL PHARMACEUTICALS INC. ( ADIL ) has paid 0.00 dividends per share and bought back -4.657145 million shares in the past 12 months
ADIAL PHARMACEUTICALS INC. ( ADIL ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
ADIAL PHARMACEUTICALS INC. ( ADIL ) Interest-bearing Debt ($MM) as of last quarter is 0
ADIAL PHARMACEUTICALS INC. ( ADIL ) Annual Working Capital Investments ($MM) are -1
ADIAL PHARMACEUTICALS INC. ( ADIL ) Book Value ($MM) as of last quarter is 5
ADIAL PHARMACEUTICALS INC. ( ADIL ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ADIAL PHARMACEUTICALS INC. ( ADIL ) has 5 million in cash on hand as of last quarter
ADIAL PHARMACEUTICALS INC. ( ADIL ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ADIAL PHARMACEUTICALS INC. ( ADIL ) has 5 common shares outstanding as of last quarter
ADIAL PHARMACEUTICALS INC. ( ADIL ) has 0 million USD of preferred stock value
Academic Scores:
ADIAL PHARMACEUTICALS INC. ( ADIL ) Altman Z-Score is -15.56 as of last quarter
ADIAL PHARMACEUTICALS INC. ( ADIL ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ADIAL PHARMACEUTICALS INC. ( ADIL ) largest shareholder is owning shares at 0.00 ($MM) value
Kevin Schuyler(an insider) Bought 700 shares of ADIAL PHARMACEUTICALS INC. ( ADIL ) for the amount of $1918.00 on 2023-09-29
1.80% of ADIAL PHARMACEUTICALS INC. ( ADIL ) is held by insiders, and 3.03% is held by institutions
ADIAL PHARMACEUTICALS INC. ( ADIL ) went public on 2018-07-30
Other ADIAL PHARMACEUTICALS INC. ( ADIL ) financial metrics:
FCF:-8.39
Unlevered Free Cash Flow:0.00
EPS:-1.50
Operating Margin:-7093.07
Gross Profit Margin:-0.44
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-149.01
Beta:1.43
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ADIAL PHARMACEUTICALS INC. ( ADIL ) :
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.